Suppr超能文献

丙型肝炎病毒基因型 4、5 和 6 NS3-NS4A 蛋白的蛋白酶和解旋酶活性。

Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins.

机构信息

Boehringer Ingelheim (Canada) Ltd, Department of Biological Sciences, 2100 Cunard St, Laval, QC, Canada.

出版信息

Biochem Biophys Res Commun. 2010 Jan 1;391(1):692-7. doi: 10.1016/j.bbrc.2009.11.122. Epub 2009 Nov 26.

Abstract

The bifunctional NS3 protease-helicase of hepatitis C virus (HCV), together with its cofactor protein NS4A, is an important target for antiviral drugs which can cure HCV infections. HCV strains are divided into six major genotypes based on sequence diversity, and the great majority of reports on NS3 have focused exclusively on genotype 1 proteins. Here we report the cloning, expression, and preliminary characterization of NS3-NS4A gene products from HCV genotypes 4, 5, and 6. This work complements our earlier characterization of genotype 2 and 3 proteins [17]. We compare NS3-NS4A protease and helicase activities of genotypes 4a, 5a, and 6a to those of common reference strains Con1 (genotype 1b) and JFH1 (genotype 2a). The specific activities of the proteases of the newly isolated proteins were similar to those of the reference proteins. Furthermore, the reference inhibitor BILN 2061 had similar activity against all of the proteins except for that of JFH1, which had an apparent K(i) that was 11-fold higher relative to Con1. RNA and DNA unwinding activities were also similar for genotypes 1, 4, 5, and 6 proteins, but significantly higher for genotype 2 JFH1. With the availability of these proteins, inhibitors developed based on their activity against genotype 1 can be tested against all the other major genotypes, providing a path to improved treatment for all HCV patients.

摘要

丙型肝炎病毒(HCV)的双功能 NS3 蛋白酶-解旋酶,与其辅助蛋白 NS4A 一起,是治疗 HCV 感染的抗病毒药物的重要靶点。根据序列差异,HCV 株分为 6 种主要基因型,大多数关于 NS3 的报道都专门针对基因型 1 蛋白。在这里,我们报告了 HCV 基因型 4、5 和 6 的 NS3-NS4A 基因产物的克隆、表达和初步特征。这项工作补充了我们之前对基因型 2 和 3 蛋白的研究[17]。我们比较了基因型 4a、5a 和 6a 的 NS3-NS4A 蛋白酶和解旋酶活性与常见参考株 Con1(基因型 1b)和 JFH1(基因型 2a)的活性。新分离蛋白的蛋白酶比活与参考蛋白相似。此外,参考抑制剂 BILN 2061 对除 JFH1 以外的所有蛋白均具有相似的活性,而 JFH1 的 K(i)值比 Con1 高 11 倍。RNA 和 DNA 解旋活性在基因型 1、4、5 和 6 蛋白之间也相似,但基因型 2 JFH1 的活性明显更高。有了这些蛋白质,基于它们对基因型 1 的活性开发的抑制剂可以针对所有其他主要基因型进行测试,为所有 HCV 患者提供了更好的治疗方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验